Miglitol

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Miglitol

Error creating thumbnail: File missing
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	US FDA: Miglitol
Pregnancy category	AU: B3 US: B (No risk in non-human studies)
Routes of administration	Oral
ATC code	A10BF02 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	Dose-dependent
Protein binding	Negligible (<4.0%)
Metabolism	Nil
Elimination half-life	2 hours
Excretion	Renal (95%)
Identifiers
IUPAC name (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl) piperidine-3,4,5-triol
CAS Number	72432-03-2
PubChem CID	441314
DrugBank	APRD01117
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C8H17NO5
Molar mass	207.224 g/mol

WikiDoc Resources for Miglitol
Articles
Most recent articles on Miglitol Most cited articles on Miglitol Review articles on Miglitol Articles on Miglitol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Miglitol Images of Miglitol Photos of Miglitol Podcasts & MP3s on Miglitol Videos on Miglitol
Evidence Based Medicine
Cochrane Collaboration on Miglitol Bandolier on Miglitol TRIP on Miglitol
Clinical Trials
Ongoing Trials on Miglitol at Clinical Trials.gov Trial results on Miglitol Clinical Trials on Miglitol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Miglitol NICE Guidance on Miglitol NHS PRODIGY Guidance FDA on Miglitol CDC on Miglitol
Books
Books on Miglitol
News
Miglitol in the news Be alerted to news on Miglitol News trends on Miglitol
Commentary
Blogs on Miglitol
Definitions
Definitions of Miglitol
Patient Resources / Community
Patient resources on Miglitol Discussion groups on Miglitol Patient Handouts on Miglitol Directions to Hospitals Treating Miglitol Risk calculators and risk factors for Miglitol
Healthcare Provider Resources
Symptoms of Miglitol Causes & Risk Factors for Miglitol Diagnostic studies for Miglitol Treatment of Miglitol
Continuing Medical Education (CME)
CME Programs on Miglitol
International
Miglitol en Espanol Miglitol en Francais
Business
Miglitol in the Marketplace Patents on Miglitol
Experimental / Informatics
List of terms related to Miglitol

For patient information, click here

Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.

Miglitol inhibits glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet.

In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.

See also

• Alpha-glucosidase inhibitor

Template:WikiDoc Sources